A Phase 1 interventional study of Belantamab in Autoimmune Diseases, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Autoimmune Diseases by GlaxoSmithKline — 1 open to participants now, 2 under way, 1 of them phase 3. Autoimmune Diseases · GlaxoSmithKline.
Among the 29 studies in Autoimmune Diseases by GlaxoSmithKline, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 1, and was the 28th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →1 of the 29 studies in Autoimmune Diseases by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
By country, each count listing its studies:
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 79 across the 25 interventional studies, 2,231 across the 4 observational. Of the 24 that completed or were terminated, 18 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Autoimmune Diseases by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Autoimmune Diseases by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but active autoimmune disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with systemic lupus erythematosus (SLE) must also meet the following inclusion criteria:
Participants with Rheumatoid Arthritis (RA) must also meet the following inclusion Criteria:
Participants with antiphospholipid syndrome (APS) must also meet the following inclusion criteria:
Clinical features attributable to antiphospholipid antibodies that are resistant to warfarin and/or heparin:
Exclusion criteria:
SLE specific exclusion:
RA specific exclusions:
APS specific exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Belantamab
Belantamab will be administered
Also known as: GSK2857914
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to Week 12
Number of participants with clinically important findings in vital signs
Time frame: Up to Week 12
Number of participants with clinically important findings in electrocardiogram
Time frame: Up to Week 12
Number of participants with clinically important findings in echocardiogram
Time frame: Up to Week 12
Number of participants with clinically important findings in hematology
Time frame: Up to Week 12
Number of participants with clinically important findings in clinical chemistry
Time frame: Up to Week 12
Number of participants with clinically important findings in urinalysis parameters
Time frame: Up to Week 12
Number of participants with clinically important finding in corneal toxicity
Time frame: Up to Week 12
Change from Baseline in Immunoglobulin (Ig) M (IgM)
Time frame: Baseline (Day 1) and up to Week 12
Area under the concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-t)] of belantamab
Time frame: Up to 12 weeks
Area under the concentration-time curve from time 0 to infinity [AUC(0-inf)] of belantamab
Time frame: Up to 12 weeks
Maximum observed plasma drug concentration [Cmax] of belantamab
Time frame: Up to 12 weeks
Number of participants with Anti-Drug Antibodies (ADAs) against belantamab
Time frame: Up to 12 weeks
Titers of ADAs against belantamab
Time frame: Up to 12 weeks
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Jul 2025, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab